Sheehan's syndrome: baseline characteristics and effect of 2 years of growth hormone replacement therapy in 91 patients in KIMS - Pfizer International Metabolic Database

Kelestimur F., Jonsson P., Molvalilar S., Gomez J., Auernhammer C., Colak R., ...Daha Fazla

EUROPEAN JOURNAL OF ENDOCRINOLOGY, cilt.152, sa.4, ss.581-587, 2005 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 152 Sayı: 4
  • Basım Tarihi: 2005
  • Doi Numarası: 10.1530/eje.1.01881
  • Dergi Adı: EUROPEAN JOURNAL OF ENDOCRINOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.581-587
  • İstanbul Üniversitesi Adresli: Hayır

Özet

Objective: Sheehan's syndrome occurs as a result of ischaemic pituitary necrosis due to severe postpartum haemorrhage. It is one of the most important causes of hypopituitarism. and hence growth hormone deficiency (GHD), in developing countries. However, little is known about the effects of growth hormone (GH) replacement therapy in patients with Sheehan's syndrome.